Bone mineral density in women newly diagnosed with breast cancer: a prospective cohort study

Fraenkel, Merav, Novack, Victor, Mizrakli, Yuval, Koretz, Michael, Siris, Ethel, Norton, Larry, Shafat, Tali, Geffen, David B (February 2022) Bone mineral density in women newly diagnosed with breast cancer: a prospective cohort study. npj Breast Cancer, 8 (1). p. 21. ISSN 2374-4677

PDF 2022.Fraenkel.bone_mineral_density.pdf Available under License Creative Commons Attribution. Download (645kB)

Abstract

Estrogen may have opposing effects on health, namely increasing the risk of breast cancer and improving bone health by increasing bone mineral density (BMD). The objective of this study was to compare dual-energy X-ray absorptiometry (DXA) BMD between women newly diagnosed with breast cancer and matched controls without breast cancer. Women newly diagnosed with breast cancer treated between April 2012 and October 2017 were prospectively enrolled. A control group was established of women with negative mammography or breast ultrasound, matched 1:1 by age, body mass index, parity, and the use of hormone replacement therapy. All those included had DXA BMD, and lab assessments at enrollment. Of 869 women with newly diagnosed breast cancer, 464 signed informed consent. Of the 344 who completed the study protocol, 284 were matched to controls. Overall, the mean age was 58 years. Compared to the control group, for the breast cancer group, the mean vitamin D level was lower (48.9 ± 19.0 vs. 53.8 ± 28.8 nmol/L, p = 0.022); and mean values were higher of total hip BMD (0.95 ± 0.14 vs. 0.92 ± 0.12 g/cm2, p = 0.002), T score (-0.38 ± 1.17 vs. -0.68 ± 0.98, p = 0.002), and Z score (0.32 ± 1.09 vs. 0.01 ± 0.88, p < 0.001). Among the women with breast cancer, no correlations were found of baseline BMD with tumor size or grade, nodal involvement, or breast cancer stage. We concluded that women with newly diagnosed breast cancer tend to have higher BMD than women with similar characteristics but without breast cancer. This implies that BMD might be considered a biomarker for breast cancer risk.

Item Type:	Paper
Subjects:	bioinformatics diseases & disorders > cancer diseases & disorders bioinformatics > genomics and proteomics organs, tissues, organelles, cell types and functions > organs types and functions > bone mineral density diseases & disorders > cancer > cancer types > breast cancer bioinformatics > genomics and proteomics > small molecules > estrogen organs, tissues, organelles, cell types and functions > organs types and functions organs, tissues, organelles, cell types and functions bioinformatics > genomics and proteomics > small molecules diseases & disorders > cancer > cancer types
CSHL Authors:	Norton, Larry
Communities:	CSHL labs > Wigler lab
SWORD Depositor:	CSHL Elements
Depositing User:	CSHL Elements
Date:	17 February 2022
Date Deposited:	23 Feb 2022 20:40
Last Modified:	11 Jan 2024 20:06
PMCID:	PMC8854387
URI:	https://repository.cshl.edu/id/eprint/40526

Actions (login required)

Administrator's edit/view item